Auxetics

Executive Summary

Auxetics is a privately held medical device company founded in 2016, headquartered in Portland, Oregon, with operations in Cambridge, Massachusetts. The company is developing a novel venous stent that leverages an auxetic structure—a geometric design that causes the stent to expand longitudinally as it widens radially. This unique mechanical behavior is engineered to better match the biomechanical properties of veins, which are more compliant and dynamic than arteries. By addressing a key limitation of conventional stents—which often fail to accommodate vessel movement and can lead to complications such as migration, fracture, or restenosis—Auxetics aims to improve outcomes for patients with venous diseases like deep vein thrombosis or post-thrombotic syndrome. As a preclinical-stage company without disclosed funding or revenue, Auxetics faces the typical risks of early-stage medtech development, including regulatory hurdles, clinical validation, and capital requirements. However, its targeted innovation in venous stenting addresses a significant unmet need, as current stent designs are primarily adapted from arterial applications. If successful, the auxetic stent could become a standard for venous interventions. The company's progress will depend on successful preclinical studies, first-in-human trials, and eventual FDA approval. Given the lack of public milestones, conviction is tempered by early-stage uncertainty.

Upcoming Catalysts (preview)

• TBDFirst-in-human study initiation60% success
• TBDSeries A or B financing round70% success
• TBDFDA breakthrough device designation50% success